WallStSmart

Dynavax Technologies Corporation (DVAX)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 4227% more annual revenue ($14.30B vs $330.51M). DVAX leads profitability with a -13.1% profit margin vs -24.6%. VTRS earns a higher WallStSmart Score of 50/100 (C-).

DVAX

Hold

45

out of 100

Grade: D+

Growth: 6.7Profit: 4.0Value: 5.0Quality: 5.8
Piotroski: 4/9Altman Z: 0.98

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVAX3 strengths · Avg: 8.7/10
EPS GrowthGrowth
69.3%10/10

Earnings expanding 69.3% YoY

Operating MarginProfitability
24.8%8/10

Strong operational efficiency at 24.8%

Revenue GrowthGrowth
17.7%8/10

17.7% revenue growth

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

DVAX4 concerns · Avg: 2.0/10
Market CapQuality
$1.82B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-7.1%2/10

ROE of -7.1% — below average capital efficiency

Altman Z-ScoreHealth
0.982/10

Distress zone — elevated risk

Profit MarginProfitability
-13.1%1/10

Currently unprofitable

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : DVAX

The strongest argument for DVAX centers on EPS Growth, Operating Margin, Revenue Growth. Revenue growth of 17.7% demonstrates continued momentum.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : DVAX

The primary concerns for DVAX are Market Cap, Return on Equity, Altman Z-Score.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

DVAX profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.

DVAX carries more volatility with a beta of 0.93 — expect wider price swings.

DVAX is growing revenue faster at 17.7% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Bottom Line

VTRS scores higher overall (50/100 vs 45/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Dynavax Technologies Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company is headquartered in Emeryville, California.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?